Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772845 | 0.84 | PKM (0.33) | PKMTSHR | |
| SCHEMBL4564855 | 0.80 | TSHR (0.35) | PKMTSHR | |
| SCHEMBL9768971 | 0.74 | PKM (0.38) | PKMTSHR | |
| SCHEMBL9724429 | 0.74 | PKM (0.38) | PKMTSHR | |
| SCHEMBL295321 | 0.74 | PKM (0.38) | PKMTSHR | |
| SCHEMBL25718526 | 0.74 | TSHR (0.38) | PKMTSHR | |
| Hydrochloric Acid SCHEMBL15054537 | 0.73 | PKM (0.37) | PKMTSHR | |
| SCHEMBL293833 | 0.71 | PKM (0.36) | PKMTSHR | |
| SCHEMBL8309740 | 0.71 | PKM (0.36) | PKMTSHR | |
| SCHEMBL9768795 | 0.70 | HTR7 (0.35) | PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| US-20040034017-A1 | 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | US | claimed |
| US-6844336-B2 | 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity | SCHERING AG (DE) | 2005-01-18 | — | — | US | disclosed |
| US-6844336-B2 | 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity | SCHERING AG (DE) | 2005-01-18 | — | — | US | disclosed |
| US-6844336-B2 | 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity | SCHERING AG (DE) | 2005-01-18 | — | — | US | disclosed |
| EP-1272481-B1 | 4-FLUOROALKYL-2H-BENZOPYRANS WITH ANTI-ESTROGENIC ACTIVITY | SCHERING AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040034017-A1 | 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20040034017-A1 | 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20040034017-A1 | 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1272481-A1 | 4-FLUOROALKYL-2H-BENZOPYRANS WITH ANTI-ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001068634-A1 | 4-FLUOROALKYL-2H-BENZOPYRANS WITH ANTI-ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | PKM 148/4885TSHR 3371/4885 |
| US-20040034017-A1 | 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity | ESR2, CYP19A1, GPER1 | PKM 1109/4885TSHR 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.